MedPath

Pegadricase

Generic Name
Pegadricase
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1040753-26-1
Unique Ingredient Identifier
50XB37EKN8
Background

Pegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).

Associated Conditions
-
Associated Therapies
-
pharmaphorum.com
·

11 blockbuster drugs to look out for in 2025

Clarivate's Drugs to Watch list highlights 11 promising drugs, including Novo Nordisk's Awiqli and CagriSema, Bristol Myers Squibb's Cobenfy, Eli Lilly and Almirall's Ebglyss, Sanofi and Alnylam's fitusiran, GSK's GSK-3536819, Amgen's Imdelltra, Moderna's mResvia, Sobi and Cartesian Therapeutics/Selecta Biosciences' SEL-212, Arvinas and Pfizer's vepdegestrant, and Exelexis' zanzalintinib, with potential to transform treatments and achieve significant sales by 2030.
contractpharma.com
·

11 Drugs to Watch in 2025

Clarivate identifies 11 drugs with potential to become blockbusters by 2030, focusing on obesity, oncology, and gene therapy. Notable drugs include AWIQLI for diabetes, CagriSema for obesity and diabetes, COBENFY for schizophrenia, and IMDELLTRA for lung cancer, among others, aiming to transform treatment paradigms.
biospace.com
·

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies Set to Revolutionize Healthcare

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize healthcare. These include AWIQLI® for diabetes, CagriSema for obesity and diabetes, COBENFY™ for schizophrenia, and others, showcasing advancements in AI, machine learning, and regulatory innovation to improve global patient care.
prnewswire.com
·

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in 2025

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize patient care. These innovations, including AWIQLI®, CagriSema, and IMDELLTRA™, promise significant advancements in treatment paradigms and patient outcomes globally.
labiotech.eu
·

Ten drugs to watch in 2025: will these therapies become blockbusters?

Clarivate's Drugs to Watch 2025 report highlights therapies predicted to become blockbusters by 2030, including CagriSema for diabetes/obesity, Awiqli for diabetes, Cobenfy for schizophrenia, Ebglyss for atopic dermatitis, Fitusiran for hemophilia, Imdelltra for lung cancer, mResvia for RSV, SEL-212 for gout, Vepdegestrant for breast cancer, and Zanzalintinib for various cancers. These drugs represent significant advancements in treatment options across therapeutic areas.

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to achieve blockbuster status or revolutionize treatment by 2030. Innovations include AI in drug discovery, next-gen GLP-1 therapies for obesity, and gene editing for personalized medicine, aiming to improve global patient care.
macaubusiness.com
·

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in Obesity, Oncology, Gene Therapy, and More

Clarivate's 2025 Drugs to Watch™ report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to redefine healthcare. These innovations, including AWIQLI® for diabetes and CagriSema for obesity, promise significant patient care advancements, leveraging AI, machine learning, and regulatory innovations for global health improvement.
newswire.ca
·

Clarivate Identifies Eleven Potential Blockbuster Therapies Set to Revolutionize Patient Care

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize patient care. These include AWIQLI® for diabetes, CagriSema for obesity, and IMDELLTRA™ for lung cancer, showcasing advancements in AI, machine learning, and regulatory innovation to improve global health outcomes.
prnewswire.com
·

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies Set to Revolutionize Healthcare by 2030

Clarivate's 2025 Drugs to Watch report highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, set to revolutionize healthcare. These drugs, leveraging AI, machine learning, and novel mechanisms, aim to address unmet medical needs, improve patient outcomes, and achieve blockbuster status by 2030.
© Copyright 2025. All Rights Reserved by MedPath